Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | multiple epidermal growth factor-like domains 6 | 0.00306532 | 0.5 | 0.5 |
Echinococcus granulosus | laminin | 0.00306532 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.00306532 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.00306532 | 0.5 | 0.5 |
Toxoplasma gondii | calcium binding egf domain-containing protein | 0.00306532 | 0.5 | 0.5 |
Schistosoma mansoni | egf-like domain protein | 0.00306532 | 0.5 | 0.5 |
Loa Loa (eye worm) | low-density lipoprotein receptor repeat class B containing protein | 0.00306532 | 0.5 | 0.5 |
Brugia malayi | Calcium binding EGF domain containing protein | 0.00306532 | 0.5 | 0.5 |
Echinococcus multilocularis | fibrillin 1 | 0.00306532 | 0.5 | 0.5 |
Echinococcus granulosus | Tolloid protein 1 | 0.00306532 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.00306532 | 0.5 | 0.5 |
Toxoplasma gondii | calcium binding egf domain-containing protein | 0.00306532 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.00306532 | 0.5 | 0.5 |
Brugia malayi | Fibulin-1 precursor | 0.00306532 | 0.5 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.00306532 | 0.5 | 0.5 |
Onchocerca volvulus | Arrow homolog | 0.00306532 | 0.5 | 0.5 |
Brugia malayi | Low-density lipoprotein receptor repeat class B containing protein | 0.00306532 | 0.5 | 0.5 |
Echinococcus multilocularis | Tolloid protein 1 | 0.00306532 | 0.5 | 0.5 |
Loa Loa (eye worm) | bone morphogenetic protein 1b | 0.00306532 | 0.5 | 0.5 |
Echinococcus multilocularis | laminin | 0.00306532 | 0.5 | 0.5 |
Schistosoma mansoni | subfamily M12A unassigned peptidase (M12 family) | 0.00306532 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (functional) | = 94 % | Antitrypanosomal activity against Trypanosoma cruzi CL Brener clone epimastigotes assessed as cell death at 25 uM after 2 days by MTT assay relative to control | ChEMBL. | 21506600 |
Activity (functional) | = 100 % | Antitrypanosomal activity against Trypanosoma cruzi Colombiana epimastigotes assessed as cell death at 25 uM after 2 days by MTT assay relative to control | ChEMBL. | 21506600 |
Activity (functional) | = 100 % | Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes assessed as cell death at 25 uM after 2 days by MTT assay relative to control | ChEMBL. | 21506600 |
GI (functional) | = 99 % | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes assessed as growth inhibition at 25 uM after 5 days relative to control | ChEMBL. | 21506600 |
IC50 (functional) | > 7 uM | Antimalarial activity after 48 hrs against chloroquine-sensitive Plasmodium falciparum 3D7 by [3H]hypoxanthine uptake | ChEMBL. | 18215443 |
ID50 (functional) | = 3 uM | Antileishmanial activity against Leishmania braziliensis MHOM/BR/00/LTB300 promastigotes assessed as cell death after 2 days by MTT assay | ChEMBL. | 21506600 |
ID50 (functional) | = 7.1 uM | Antitrypanosomal activity against Trypanosoma cruzi Y epimastigotes assessed as cell death after 2 days by MTT assay | ChEMBL. | 21506600 |
ID50 (functional) | = 16.4 uM | Antitrypanosomal activity against Trypanosoma cruzi CL Brener clone epimastigotes assessed as cell death after 2 days by MTT assay | ChEMBL. | 21506600 |
ID50 (functional) | = 11300 uM | Antitrypanosomal activity against Trypanosoma cruzi Tulahuen 2 epimastigotes assessed as growth inhibition after 5 days | ChEMBL. | 21506600 |
Inhibition (functional) | = 90 % | Antimicrobial activity against Mycobacterium tuberculosis H37Rv at 6.25 ug/ml by microplate alamar blue assay | ChEMBL. | 19058970 |
MIC (functional) | < 0.2 ug ml-1 | Antimicrobial activity against Mycobacterium tuberculosis H37Rv by microplate alamar blue assay | ChEMBL. | 19058970 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 18215443 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.